Gilead Sciences financials
$151.28−0.61%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $29.44B | $28.75B | $27.12B | $27.28B | $27.30B | $24.69B | $22.45B | $22.13B | $26.11B | $30.39B |
| Gross profit | $23.21B | $22.50B | $20.62B | $21.62B | $20.70B | $20.12B | $17.77B | $17.27B | $21.74B | $26.13B |
| Gross margin | 78.8% | 78.3% | 76.0% | 79.3% | 75.8% | 81.5% | 79.2% | 78.1% | 83.3% | 86.0% |
| Operating income | $10.02B | $1.66B | $7.61B | $7.33B | $9.92B | $4.07B | $4.29B | $8.20B | $14.12B | $17.63B |
| Net income | $8.51B | $480.0M | $5.67B | $4.59B | $6.22B | $123.0M | $5.39B | $5.46B | $4.63B | $13.50B |
| Net margin | 28.9% | 1.7% | 20.9% | 16.8% | 22.8% | 0.5% | 24.0% | 24.7% | 17.7% | 44.4% |
| Diluted EPS | $6.78 | $0.38 | $4.50 | $3.64 | $4.93 | $0.10 | $4.22 | $4.17 | $3.51 | $9.94 |
| EBITDA | $14.40B | $13.27B | $11.50B | $13.08B | $12.91B | $5.55B | $5.69B | $9.63B | $15.41B | $18.79B |
| Operating cash flow | $10.02B | $10.83B | $8.01B | $9.07B | $11.38B | $8.17B | $9.14B | $8.40B | $11.90B | $17.05B |
| Free cash flow | $9.46B | $10.30B | $7.42B | $8.34B | $10.80B | $7.52B | $8.32B | $7.48B | $11.31B | $16.30B |
| Diluted shares | 1,255.0M | 1,255.0M | 1,258.0M | 1,262.0M | 1,262.0M | 1,263.0M | 1,277.0M | 1,308.0M | 1,319.0M | 1,358.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $7.56B | $9.99B | $6.08B | $5.41B | $5.34B | $6.00B |
| Short-term investments | $68.0M | $0.00 | $1.18B | $973.0M | $1.18B | $1.41B |
| Total debt | $24.94B | $26.71B | $24.99B | $25.23B | $26.70B | $31.40B |
| Total assets | $59.02B | $58.99B | $62.13B | $63.17B | $67.95B | $68.41B |
| Total liabilities | $36.41B | $39.75B | $39.38B | $41.96B | $46.89B | $50.19B |
| Shareholders' equity | $22.62B | $19.25B | $22.75B | $21.21B | $21.06B | $18.22B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology